HAE vs. MMSI, ICUI, GKOS, AXNX, IRTC, PRCT, TNDM, GMED, NARI, and INSP
Should you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include Merit Medical Systems (MMSI), ICU Medical (ICUI), Glaukos (GKOS), Axonics (AXNX), iRhythm Technologies (IRTC), PROCEPT BioRobotics (PRCT), Tandem Diabetes Care (TNDM), Globus Medical (GMED), Inari Medical (NARI), and Inspire Medical Systems (INSP). These companies are all part of the "surgical & medical instruments" industry.
Haemonetics (NYSE:HAE) and Merit Medical Systems (NASDAQ:MMSI) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends.
99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 99.7% of Merit Medical Systems shares are owned by institutional investors. 1.8% of Haemonetics shares are owned by insiders. Comparatively, 3.7% of Merit Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Haemonetics has a net margin of 9.97% compared to Merit Medical Systems' net margin of 7.94%. Haemonetics' return on equity of 22.37% beat Merit Medical Systems' return on equity.
Haemonetics has higher revenue and earnings than Merit Medical Systems. Haemonetics is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.
In the previous week, Merit Medical Systems had 16 more articles in the media than Haemonetics. MarketBeat recorded 26 mentions for Merit Medical Systems and 10 mentions for Haemonetics. Haemonetics' average media sentiment score of 0.95 beat Merit Medical Systems' score of 0.73 indicating that Haemonetics is being referred to more favorably in the media.
Haemonetics currently has a consensus target price of $104.67, indicating a potential upside of 10.44%. Merit Medical Systems has a consensus target price of $92.78, indicating a potential upside of 16.63%. Given Merit Medical Systems' stronger consensus rating and higher possible upside, analysts clearly believe Merit Medical Systems is more favorable than Haemonetics.
Merit Medical Systems received 31 more outperform votes than Haemonetics when rated by MarketBeat users. Likewise, 68.90% of users gave Merit Medical Systems an outperform vote while only 60.86% of users gave Haemonetics an outperform vote.
Haemonetics has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500. Comparatively, Merit Medical Systems has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.
Summary
Haemonetics and Merit Medical Systems tied by winning 9 of the 18 factors compared between the two stocks.
Get Haemonetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Haemonetics Competitors List
Related Companies and Tools
